Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
대표청구항▼
1. A composition comprising isolated dendritic cells that present on human leukocyte antigen (HLA) on their surface peptide epitopes of the following six antigens: tyrosinase-related protein (TRP)-2, Melanoma-associated Antigen-1 (MAGE-1), HER-2, interleukin-13 receptor α2 (IL-13 receptor α2), gp100
1. A composition comprising isolated dendritic cells that present on human leukocyte antigen (HLA) on their surface peptide epitopes of the following six antigens: tyrosinase-related protein (TRP)-2, Melanoma-associated Antigen-1 (MAGE-1), HER-2, interleukin-13 receptor α2 (IL-13 receptor α2), gp100, and Antigen isolated from Immunoselected Melanoma-2 (AIM-2), wherein the dendritic cells acquired the peptide epitopes in vitro by exposure to six synthetic peptides from the six antigens each of which are 9 to 13 amino acids in length and wherein five of the six synthetic peptides comprise the following amino acid sequences: (SEQ ID NO: 3)RSDSGQQARYfrom AIM-2;(SEQ ID NO: 4)EADPTGHSYfrom MAGE-1;(SEQ ID NO: 5)SVYDFFVWLfrom TRP-2;(SEQ ID NO: 37)VMAGVGSPYVfrom HER-2;and(SEQ ID NO: 8)WLPFGFILIfrom IL-13 receptor α2. 2. The composition of claim 1, wherein the composition comprises between 105 and 108 dendritic cells. 3. The composition of claim 1, wherein the composition comprises autologous dendritic cells. 4. A composition comprising isolated dendritic cells that present on HLA on their surface peptide epitopes of the following six antigens: tyrosinase-related protein (TRP)-2, Melanoma-associated Antigen-1 (MAGE-1), HER-2, interleukin-13 receptor α2 (IL-13 receptor α2), gp100, and Antigen isolated from Immunoselected Melanoma-2 (AIM-2), wherein the dendritic cells acquired the peptide epitopes in vitro by exposure to six synthetic peptides of the six antigens each of which are 9 to 13 amino acids in length and comprise the following amino acid sequences: (SEQ ID NO: 3)RSDSGQQARYfrom AIM-2;(SEQ ID NO: 4)EADPTGHSYfrom MAGE-1;(SEQ ID NO: 5)SVYDFFVWLfrom TRP-2;(SEQ ID NO: 6)ITDQVPFSVfrom gp100;(SEQ ID NO: 37)VMAGVGSPYVfrom HER-2;and(SEQ ID NO: 8)WLPFGFILIfrom IL-13 receptor α2. 5. The composition of claim 4, wherein the composition comprises between 105 and 108 dendritic cells. 6. The composition of claim 4, wherein the composition comprises autologous dendritic cells. 7. A method for preparing a cell vaccine for treating a neural cancer, the method comprising: obtaining bone marrow derived mononuclear cells from a patient,culturing the mononuclear cells in vitro under conditions in which mononuclear cells become adherent to a culture vessel,selecting a subset of the mononuclear cells comprising adherent cells,culturing the adherent cells in the presence of one or more cytokines under conditions in which the adherent cells differentiate into dendritic cells, andculturing the dendritic cells in the presence of six synthetic peptides,each of which are 9 to 13 amino acids in length, of the following six antigens: TRP-2, MAGE-1, HER-2, IL-13 receptor α2, gp100, and AIM2, wherein five of the six synthetic peptides comprise the following amino acid sequences: (SEQ ID NO: 3)RSDSGQQARYfrom AIM-2;(SEQ ID NO: 4)EADPTGHSYfrom MAGE-1;(SEQ ID NO: 5)SVYDFFVWLfrom TRP-2;(SEQ ID NO: 37)VMAGVGSPYVfrom HER-2;and(SEQ ID NO: 8)WLPFGFILIfrom IL-13 receptor α2,under conditions in which the dendritic cells present the peptides on human leukocyte antigens, thereby preparing a cell vaccine. 8. The method of claim 7, wherein the neural cancer is a glioma. 9. The method of claim 7, wherein the neural cancer is glioblastoma multiforme. 10. The method of claim 7, wherein the neural cancer is an astrocytoma. 11. The method of claim 7, wherein the one or more cytokines comprise granulocyte monocyte-colony stimulating factor, interleukin-4, and tumor necrosis factor-alpha.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (47)
Rosenberg Steven A. (Bethesda MD), Adoptive immunotherapy as a treatment modality in humans.
Graus, Yvo Maria Franciscus; Smit, Hobbe Friso; Osterhaus, Albertus Dominicus Marcellinus Erasmus; Hageman, Robert Johan Joseph, Chlorogenic acid and an analog thereof for immune system stimulation.
Altman John D. (San Carlos CA) McHeyzer-Williams Michael G. (Menlo Park CA) Davis Mark M. (Atherton CA), Compositions and methods for the detection, quantitation and purification of antigen-specific T cells.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is a.
Hideaki Tahara JP; Michael T. Lotze ; Yasuhiko Nishioka JP, In situ injection of antigen-presenting cells with genetically enhanced cytokine expression.
Steinman Ralph M. ; Inaba Kayo,JPX ; Schuler Gerold,ATX, Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens.
Steinman Ralph M. ; Inaba Kayo,JPX ; Schuler Gerold,ATX, Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens.
Cohen Peter A. ; Czerniecki Brian J. ; Koski Gary K. ; Weng David E. ; Carter Charles ; Ojeifo John O. ; Schwartz Gretchen N., Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells.
Cohen Peter A. (Bethesda MD) Czerniecki Brian J. (Gaithersburg MD) Carter Charles (Gaithersburg MD) Fowler Daniel H. (Bethesda MD) Kim Hyun (Rochester MN), Method for isolating dendritic cells.
Edward L. Nelson ; Susan L Strobl, Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells.
Storkus Walter J. ; Lotze Michael T., Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients.
Boon Thierry,BEX ; Van Der Bruggen Pierre,BEX ; Van Den Eynde Benoit,BEX ; Van Pel Aline,BEX ; De Plaen Etienne,BEX ; Lurquin Christophe,BEX ; Chomez Patrick,BEX ; Traversari Catia,ITX, Tumor rejection antigen precursors, tumor rejection antigens and uses thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.